Biolake,China’s Pharmaceutical Valley

By Li Mo

Translation by Liu Jie

Biolake,China’s Pharmaceutical Valley

By Li Mo

Translation by Liu Jie

How long does it take an industry to develop from nothing into a powerhouse after its conception?

Biolake, or the Wuhan National Bio-industry Base, will tell you:only 9 years!

It is reported that Biolake in the Wuhan Optics Valley has already taken on 50 projects approved and included in National Major Special Projects for Drug Invention and Manufacturing Technology, and more than 300 on-going projects for new drugs.

Among them, 22 Category I new drugs have made it to clinics, including OsrHSA by Wuhan Healthgen Biotechnology,M802—HER2×CD3 by Wuhan YZY Biopharma, and PUDK-HGF by Humanwell Group.

Going back to the year of 2008,when the global financial crisis was at its peak, Biolake laid its foundation at the foot of Erfei Hill, which was then a desolate place to the southeast of Wuhan.

Hearing the news, the world’s top pharmaceutical enterprise,Pfizer Inc. came to China.Fresenius, the first Fortune 500 biotech company which set up a manufacturing base in Central China also came. Soon, other industry magnates like Thermo Fisher, Honeywell, Sanofi Pasteur, Sino-pharm Group,Menarini, China National Seed Group, BGI Genomics, Wuxi AppTec., and United Imaging all followed suit.

Within a couple of years, eight Fortune 500 companies and 50 listed companies set up their regional headquarters, R&D Centers or manufacturing bases in Biolake.

In 2016, Biolake achieved its first great breakthrough: The general income of the industry reached 100.5 billion yuan, and it has drawn 1,200 enterprises into the park.

As one of Wuhan’s three emerging industries of strategic importance, the health care industry of the Optics Valley has been growing annually by a compound rate of 30% over the past few years, ranking in the top three in the bioengineering and pharmaceutical industries of national high-tech zones in terms of comprehensive competitiveness, which laid a solid foundation for the industrial boom of Biolake.

In the field of biomedical engineering, eight of Biolake’s projects have been approved and included in National Major Special Projects for Scientific Instruments and Equipment Development. Over 400 medical apparatuses and instruments of Category II and above have been approved of entry into the market.

In precision medicine,a national center for the production of gene detection devices and technical application demonstrations was built, which has developed the first secondgeneration high throughput gene sequencer, and the fi rst device for capturing circulating tumor cells in China.

In bio-agriculture, the first new species of trans-genetic rice in China and the first rice whole genome breeding chip in the world have been developed in Biolake. In addition, the Honglian-type hybrid rice developed by Wuhan University,which now has its manufacturing base in Biolake, has been planted on nearly seven million hectares of farmland. The planting areas of over 50 new species of crops including cotton and rape developed in Biolake now have been increased to the largest of their type in the country. ?

9年50個(gè)新藥獲國(guó)家重大專(zhuān)項(xiàng)

一個(gè)產(chǎn)業(yè)的孕育，從無(wú)到有，從有到強(qiáng)，耗時(shí)幾載？

東湖高新區(qū)光谷生物城給出的答案：9年！

武漢國(guó)家生物產(chǎn)業(yè)基地發(fā)布數(shù)據(jù)顯示，光谷生物城已有50個(gè)項(xiàng)目獲國(guó)家新藥創(chuàng)制科技重大專(zhuān)項(xiàng)立項(xiàng)，300多個(gè)新藥項(xiàng)目在研。

其中，禾元生物的植物源重組人血清白蛋白注射液、友芝友制藥的注射用重組抗HER2和CD3人源化雙特異性抗體、人福醫(yī)藥的重組質(zhì)粒-肝細(xì)胞生長(zhǎng)因子注射液等22個(gè)一類(lèi)新藥進(jìn)入臨床。

時(shí)光倒回2008年，全球金融危機(jī)寒流彌漫。武漢東南荒煙蔓草的二妃山下，光谷生物城奠基。

全球第一制藥企業(yè)美國(guó)輝瑞來(lái)了，首個(gè)在華中設(shè)立生產(chǎn)基地的生物500強(qiáng)費(fèi)森尤斯來(lái)了。賽默飛世爾、霍尼韋爾、賽諾菲巴斯德、國(guó)藥集團(tuán)、美納里尼、中種集團(tuán)、華大基因、藥明康德、聯(lián)影醫(yī)療等行業(yè)巨頭都來(lái)了。

幾年間，8家世界500強(qiáng)、50家上市企業(yè)在光谷生物城設(shè)立區(qū)域總部、研發(fā)中心或生產(chǎn)基地。

2016年，光谷生物城首次實(shí)現(xiàn)“兩個(gè)一千”突破，產(chǎn)業(yè)總收入跨越千億大關(guān)，達(dá)到1005億元，園區(qū)聚集企業(yè)1200多家。

作為武漢三大戰(zhàn)略性新興產(chǎn)業(yè)之一，過(guò)去幾年，光谷生命健康產(chǎn)業(yè)以30%的年均復(fù)合增長(zhǎng)率高速奔跑，位居國(guó)家高新區(qū)生物醫(yī)藥產(chǎn)業(yè)綜合競(jìng)爭(zhēng)力前三甲，為“藥谷”的產(chǎn)業(yè)起飛奠定堅(jiān)實(shí)基礎(chǔ)。

在生物醫(yī)學(xué)工程領(lǐng)域，光谷生物城還有8個(gè)項(xiàng)目獲得國(guó)家重大科學(xué)儀器設(shè)備開(kāi)發(fā)專(zhuān)項(xiàng)立項(xiàng)，400多個(gè)二類(lèi)以上醫(yī)療器械產(chǎn)品獲批上市。

在精準(zhǔn)診療領(lǐng)域，建設(shè)了國(guó)家級(jí)基因檢測(cè)產(chǎn)品生產(chǎn)和技術(shù)應(yīng)用示范中心，研發(fā)出全國(guó)首臺(tái)二代高通量基因測(cè)序儀、全國(guó)首臺(tái)循環(huán)腫瘤細(xì)胞捕獲儀。

在生物農(nóng)業(yè)領(lǐng)域，誕生全國(guó)首個(gè)轉(zhuǎn)基因水稻新品種、全球首張水稻全基因組育種芯片。“紅蓮型”雜交水稻累計(jì)推廣面積破億畝，棉花、油菜等50多個(gè)新品系種植推廣面積全國(guó)第一。?

中國(guó)“藥谷”千億元產(chǎn)業(yè)啟航

文/李墨 譯/劉潔